Published in:
Open Access
01-04-2019 | Empagliflozin | Research Letter
Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1
Authors:
Julian Mustroph, Charlotte M. Lücht, Olivia Wagemann, Thomas Sowa, Karin P. Hammer, Can M. Sag, Daniel Tarnowski, Andreas Holzamer, Steffen Pabel, Bo Eric Beuthner, Samuel Sossalla, Lars S. Maier, Stefan Wagner
Published in:
Diabetologia
|
Issue 4/2019
Login to get access
Excerpt
To the Editor: The results of the Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) showed that the sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin reduced mortality and hospitalisation due to heart failure (HF) in high-risk diabetic patients [
1]. We have previously reported that empagliflozin improved contractile function in human cardiomyocytes isolated from individuals with HF, as well as myocytes from a mouse model of HF by transverse aortic constriction (TAC) [
2]. However, we have shown that SGLT2 is not expressed in healthy or failing myocardium. …
